![]()
|
|
||||||||
J. Biol. Chem., Vol. 278, Issue 9, 6992-7000, February 28, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Centre de Recherche en Infectiologie, Hôpital CHUL,
Centre Hospitalier, Universitaire de Québec and Département
de Biologie Médicale, Faculté de Médecine,
Université Laval, Ste-Foy, Québec G1V 4G2, Canada
Protein-tyrosine phosphatase
(PTP) inhibitors are potent activators of T lymphocytes, most likely by
affecting the early steps of T cell receptor (TCR) signaling. We have
analyzed the effect of the PTP inhibitor bisperoxovanadium (bpV) on
expression of the human cyclooxygenase 2 (COX-2) gene, which is induced
following TCR triggering. Here we show that COX-2 promoter activity is
markedly up-regulated following exposure of Jurkat T cells to
bpV(pic). Interestingly enough, treatment of Jurkat cells with
cyclic AMP-elevating agents such as forskolin, in combination with bpV,
resulted in a more important COX-2 transcriptional activation. Such
activation is inhibited by the immunosuppressive drugs FK506 and
cyclosporin A. The two nuclear factor of activated T cells (NFAT)
binding sites located within the COX-2 promoter region are involved in bpV-mediated positive effect on COX-2 promoter. Electromobility shift
assays showed that NFAT1 and activator protein-1 are both translocated to the nucleus following bpV treatment. The active participation of p56lck, ZAP-70,
p36LAT, and calcium in the
bpV-dependent signaling cascade leading to COX-2
transcriptional activation was demonstrated using deficient cell lines
and specific inhibitors. Although several PTPs are most likely targeted
by bpV, our data suggest that the bpV-mediated signaling cascade is
initiated by inhibition of SHP-1, which leads to phosphorylation
of p56lck and ZAP-70 and, ultimately, to NFAT
and activator protein-1 nuclear translocation. These results suggest
that PTP inhibitors can activate COX-2 gene expression in a manner very
similar to the stimulation induced by TCR triggering.
Recipient of a Tier 1 Canada Research Chair in Human
Immuno-Retrovirology. To whom correspondence should be addressed:
Laboratoire d'Immuno-Rétrovirologie Humaine, Centre de Recherche
en Infectiologie, RC709, Hôpital CHUL, Centre Hospitalier
Universitaire de Québec, 2705 boul. Laurier, Ste-Foy,
Québec G1V 4G2, Canada. Tel.: 418-654-2705; Fax: 418-654-2212;
E-mail: michel.j.tremblay@crchul.ulaval.ca.
This article has been cited by other articles:
![]() |
L. Castaldi, C. Serra, F. Moretti, G. Messina, R. Paoletti, M. Sampaolesi, A. Torgovnick, M. Baiocchi, F. Padula, A. Pisaniello, et al. Bisperoxovanadium, a phospho-tyrosine phosphatase inhibitor, reprograms myogenic cells to acquire a pluripotent, circulating phenotype FASEB J, November 1, 2007; 21(13): 3573 - 3583. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-F. Fortin, C. Barat, Y. Beausejour, B. Barbeau, and M. J. Tremblay Hyper-responsiveness to Stimulation of Human Immunodeficiency Virus-infected CD4+ T Cells Requires Nef and Tat Virus Gene Products and Results from Higher NFAT, NF-{kappa}B, and AP-1 Induction J. Biol. Chem., September 17, 2004; 279(38): 39520 - 39531. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |